- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Lennox-Gastaut Syndrome (LGS)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 807.5KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 188.1KB)
Fenfluramine – November 2025
Fenfluramine: Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL; Fintepla® - November 2025
Last updated
5 November 2025